The glioblastoma drug development space has been energized by Merck’s acquisition of Modifi Bio last December. This landmark deal has sparked renewed hope in a field long challenged by limited investment and clinical breakthroughs.
Looking ahead to 2026, it’s crucial to sustain this momentum. The 7th Glioblastoma Drug Development Summit is your essential platform for accelerating new treatments and continuing this vital progress.